60 DEGREES PHARMA INC (SXTP)
US83006G1040 - Common Stock
Taking everything into account, SXTP scores 2 out of 10 in our fundamental rating. SXTP was compared to 193 industry peers in the Pharmaceuticals industry. The financial health of SXTP is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SXTP is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SXTP has reported negative net income.
In the past year SXTP has reported a negative cash flow from operations.
1.2 Ratios
Looking at the Return On Assets, with a value of -113.00%, SXTP is doing worse than 78.53% of the companies in the same industry.
The Return On Equity of SXTP (-138.85%) is worse than 64.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113% | ||
| ROE | -138.85% | ||
| ROIC | N/A |
ROA(3y)-277.62%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 10.73%, SXTP is in line with its industry, outperforming 49.21% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for SXTP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SXTP has more shares outstanding
SXTP has a better debt/assets ratio than last year.
2.2 Solvency
SXTP has an Altman-Z score of -9.06. This is a bad value and indicates that SXTP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.06, SXTP is doing worse than 71.73% of the companies in the same industry.
SXTP has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
SXTP has a Debt to Equity ratio (0.02) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.06 |
ROIC/WACCN/A
WACC4.64%
2.3 Liquidity
A Current Ratio of 5.26 indicates that SXTP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.26, SXTP is in the better half of the industry, outperforming 68.06% of the companies in the same industry.
SXTP has a Quick Ratio of 4.91. This indicates that SXTP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.91, SXTP is in the better half of the industry, outperforming 67.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 4.91 |
3. Growth
3.1 Past
The earnings per share for SXTP have decreased strongly by -230.74% in the last year.
SXTP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -35.93%.
The Revenue for SXTP have been decreasing by -51.20% on average. This is quite bad
EPS 1Y (TTM)-230.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.06%
Revenue 1Y (TTM)-35.93%
Revenue growth 3Y-51.2%
Revenue growth 5YN/A
Sales Q2Q%164.71%
3.2 Future
The Earnings Per Share is expected to grow by 25.52% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 105.77% on average over the next years. This is a very strong growth
EPS Next Y55.4%
EPS Next 2Y35.33%
EPS Next 3Y25.52%
EPS Next 5YN/A
Revenue Next Year281.8%
Revenue Next 2Y228.02%
Revenue Next 3Y105.77%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SXTP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SXTP's earnings are expected to grow with 25.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.33%
EPS Next 3Y25.52%
5. Dividend
5.1 Amount
SXTP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
60 DEGREES PHARMA INC
NASDAQ:SXTP (12/18/2024, 2:32:47 PM)
1.43
-0.05 (-3.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.29M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113% | ||
| ROE | -138.85% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.26 | ||
| Quick Ratio | 4.91 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-230.74%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y55.4%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-35.93%
Revenue growth 3Y-51.2%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y